Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18FDG and 64Cu-DOTA-Trastuzumab Positron Emission Tomography Studies.

John Whitman¹, Vikram Adhikarla², Lusine Tumyan³, Joanne Mortimer⁴, Wei Huang^5,6, Russell Rockne², Joesph R Peterson¹, John Cole¹

¹SimBioSys Inc, Chicago, IL.

²Division of Mathematical Oncology and Computational Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA.

³Department of Radiology, City of Hope National Medical Center, Duarte, CA.

⁴Department of Medical Oncology and Medical Therapeutics Research, City of Hope National Medical Center, Duarte, CA.

⁵Advanced Imaging Research Center, Oregon Health and Science University, Portland, OR.

⁶Knight Cancer Institute, Oregon Health and Science University, Portland, OR.

PubMed PMC DOI PDF

Abstract

PURPOSE: Perfusion modeling presents significant opportunities for imaging biomarker development in breast cancer but has historically been held back by the need for data beyond the clinical standard of care (SoC) and uncertainty in the interpretability of results. We aimed to design a perfusion model applicable to breast cancer SoC dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) se…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.